|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.38 USD | -6.90% |
|
-31.83% | -1.91% |
| 07-31 | Novo Nordisk Shares Sink After Heart Disease Drug Candidate Fails Late-Stage Trial | MT |
| 07-31 | Wedbush Adjusts Monte Rosa Therapeutics Price Target to $27 From $37, Maintains Outperform Rating | MT |
Company Valuation: Monte Rosa Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 949.7 | 368.3 | 282.8 | 426.4 | 1,021 | 1,396 | - | - |
| Change | - | -61.22% | -23.21% | 50.74% | 139.48% | 36.68% | - | - |
| Enterprise Value (EV) | 603.6 | 105.5 | 50.43 | 54.22 | 1,021 | 1,396 | 1,396 | 1,396 |
| Change | - | -82.52% | -52.19% | 7.5% | 1,783.24% | 36.68% | 0% | 0% |
| P/E | -6.9x | -3.31x | -2.15x | -7.08x | -34.1x | -9.98x | -9x | -7.74x |
| PBR | 2.75x | 1.32x | 1.58x | 1.91x | - | - | - | - |
| PEG | - | 0.1x | -0.1x | 0.1x | 0.6x | -0x | -0.8x | -0.5x |
| Capitalization / Revenue | - | - | - | 5.64x | 8.26x | 31.4x | 24x | 38.6x |
| EV / Revenue | - | - | - | 0x | 0x | 31.4x | 24x | 38.6x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -7.47x | -6.69x | -5.45x |
| EV / FCF | -0x | -0x | -0x | 0x | -0x | -16.3x | -26x | -29.4x |
| FCF Yield | -7.28% | -28.6% | -22.2% | 8.91% | -2.69% | -6.13% | -3.85% | -3.4% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -2.96 | -2.3 | -2.63 | -0.98 | -0.46 | -1.656 | -1.836 | -2.134 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | 75.62 | 123.7 | 44.48 | 58.17 | 36.2 |
| EBITDA | -70.75 | -108.6 | -137.1 | -72.99 | - | - | - | - |
| EBIT 1 | -72.88 | -112.4 | -143.3 | -81.11 | -54.21 | -186.9 | -208.7 | -256 |
| Net income 1 | -73.96 | -108.5 | -135.4 | -72.7 | -38.63 | -167.3 | -193.9 | -242.1 |
| Net Debt | -346.1 | -262.8 | -232.4 | -372.1 | - | - | - | - |
| Reference price 2 | 20.42 | 7.61 | 5.65 | 6.94 | 15.68 | 16.52 | 16.52 | 16.52 |
| Nbr of stocks (in thousands) | 46,506 | 48,399 | 50,062 | 61,436 | 65,118 | 84,479 | - | - |
| Announcement Date | 29/03/22 | 16/03/23 | 14/03/24 | 20/03/25 | 17/03/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -9.98x | - | - | - | 1.4B | |
| 32.83x | 5.9x | 17.55x | 0.98% | 48.53B | |
| -23.41x | 351.08x | -21.45x | -.--% | 39.87B | |
| 30.42x | 3.04x | 13.11x | -.--% | 38.68B | |
| 46.94x | 4.76x | 30.78x | -.--% | 35.13B | |
| 28.41x | 8.22x | 20.66x | 0.41% | 29.79B | |
| 32.82x | 5.37x | 24.39x | -.--% | 16.11B | |
| 22.67x | 1.99x | 8.61x | 1.17% | 13.61B | |
| 25.33x | 1.86x | 11.4x | -.--% | 12.62B | |
| Average | 20.67x | 47.78x | 13.13x | 0.32% | 26.19B | |
| Weighted average by Cap. | 23.23x | 63.80x | 12.18x | 0.32% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- GLUE Stock
- Valuation Monte Rosa Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
